Patents by Inventor Roger A. Greenberg

Roger A. Greenberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11161865
    Abstract: The present disclosure relates to compounds of Formula I and II, wherein R1-R20 and FL are defined herein. Also provided are methods of targeting alpha-radiation to poly(ADP-ribose)polymerase 1 (PARP-1) enzyme expression, reducing proliferation of cancer cells, reducing proliferation of cancer cells, detecting intact and enzymatically active poly(ADP-ribose)polymerase 1 (PARP-1) enzyme expression, detecting PARP-1 enzyme expression in a subjects tissue sample, monitoring cancer treatment in a subject, or detecting a PARP-1 receptive cancer in a subject.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: November 2, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Robert H. Mach, Sean Reilly, Mehran Makvandi, Kuiying Xu, Daniel A. Pryma, Roger A. Greenberg
  • Publication number: 20200109156
    Abstract: The present disclosure relates to compounds of Formula I and II, wherein R1-R20 and FL are defined herein. Also provided are methods of targeting alpha-radiation to poly(ADP-ribose)polymerase 1 (PARP-1) enzyme expression, reducing proliferation of cancer cells, reducing proliferation of cancer cells, detecting intact and enzymatically active poly(ADP-ribose)polymerase 1 (PARP-1) enzyme expression, detecting PARP-1 enzyme expression in a subjects tissue sample, monitoring cancer treatment in a subject, or detecting a PARP-1 receptive cancer in a subject.
    Type: Application
    Filed: May 24, 2018
    Publication date: April 9, 2020
    Inventors: Robert H. MACH, Sean REILLY, Mehran MAKVANDI, Kuiying XU, Daniel A. PRYMA, Roger A. GREENBERG
  • Publication number: 20140206002
    Abstract: The disclosed subject matter is based on the discovery that a mutation (a single nucleotide polymorphism or “SNP”) in the gene encoding Abraxas (also referred to as ABRA1, CCDC98 or FAM175A), is associated with susceptibility to cancer, e.g., breast cancer. In particular, the disclosed subject matter is based on the identification of a heterozygous alteration in the Abraxas gene that is associated with breast cancer and specifically correlated with familial cancer. Accordingly, the SNP disclosed herein is useful for diagnosing, prognosing, screening for, and evaluating predisposition to cancer in humans. The disclosed subject matter also provides nucleic acid molecules containing the SNP, methods and reagents for the detection of the SNP, and assays or kits for detection of the SNP.
    Type: Application
    Filed: January 17, 2014
    Publication date: July 24, 2014
    Inventors: Roger A. Greenberg, Robert Winqvist, Szilvia Solyom, Katri Pylkas
  • Publication number: 20090111157
    Abstract: This invention provides for murine telomerase reverse transcriptase (mTERT) enzyme proteins and nucleic acids, including methods for isolating and expressing these nucleic acids and proteins, which have application to the control of cell proliferation and aging, including the control of age-related diseases, such as cancer.
    Type: Application
    Filed: June 28, 2007
    Publication date: April 30, 2009
    Applicant: Geron Corporation
    Inventors: Gregg B. Morin, Richard Allsopp, Ronald A. DePinho, Roger A. Greenberg
  • Publication number: 20040253701
    Abstract: This invention provides for murine telomerase reverse transcriptase (mTERT) enzyme proteins and nucleic acids, including methods for isolating and expressing these nucleic acids and proteins, which have application to the control of cell proliferation and aging, including the control of age-related diseases, such as cancer.
    Type: Application
    Filed: June 7, 2004
    Publication date: December 16, 2004
    Inventors: Gregg B. Morin, Richard Allsopp, Ronald A. De Pinho, Roger A. Greenberg
  • Patent number: 6767719
    Abstract: This invention provides for murine telomerase reverse transcriptase (mTERT) enzyme proteins and nucleic acids, including methods for isolating and expressing these nucleic acids and proteins, which have application to the control of cell proliferation and aging, including the control of age-related diseases, such as cancer.
    Type: Grant
    Filed: March 16, 1998
    Date of Patent: July 27, 2004
    Assignees: Geron Corporation, Albert Einstein College of Medicine of Yeshiva University, a division of Yeshiva University
    Inventors: Gregg B. Morin, Richard Allsopp, Ronald A. DePinho, Roger A. Greenberg